R

ise and shine, everyone, and how are you today? Puffy gray clouds are hovering over the Pharmalot campus, where the official mascots are happily snoozing and the shortest of short people has left for the local schoolhouse. As for us, we are considering our to-do list and brewing a needed cup of stimulation, since we anticipate another busy day. No doubt, you can relate. So time to get cracking. Here are some items of interest to get you started. Have a wonderful day and drop us a line when something interesting arises …

Galena Biopharma chief executive Mark Schwartz abruptly stepped down as chief executive and president — and resigned his seat on the board — on Tuesday, although no reason was given. The move, however, comes shortly after the biotech disclosed a criminal investigation by the US attorney’s office in New Jersey and the US Department of Justice into marketing of its Abstral painkiller. Schwartz had headed the company since 2014.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.